Johnson & Johnson Q2 Earnings: Lifts Annual Outlook On Strong Sales Growth From MedTech Business
Portfolio Pulse from Vandana Singh
Johnson & Johnson (JNJ) has reported Q2 FY23 adjusted earnings of $2.80 per share, beating the consensus of $2.62. Sales increased 6.3% to $25.5 billion, beating the consensus of $24.63 billion. The company has lifted its annual outlook due to strong sales growth from its MedTech business. JNJ shares are up 1.11% at $160.50 during the premarket session.
July 20, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson reported strong Q2 FY23 earnings and sales, beating consensus estimates. The company also raised its annual outlook, primarily due to strong sales growth from its MedTech business.
Johnson & Johnson's strong Q2 FY23 earnings and sales, which beat consensus estimates, along with the raised annual outlook due to strong MedTech sales, are positive indicators for the company's financial health. This is likely to instill confidence in investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100